Veloxis Restructures to Focus on Commercializing Once-Daily Immunosuppressant – Genetic Engineering News

Veloxis Pharmaceuticals is considering cutting its workforce by 40-50% and pulling the plug on all its pipeline and early R&D projects in order to free up all existing resources for completing development and commercialization of lead …